Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivus Resubmits Qnexa, But Limits Its Market Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.

You may also be interested in...



Financings Of The Fortnight Puts On The Weight

Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.

Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity

FDA appears to be testing weight loss agents against an easier-to-meet threshold for cardiovascular risk compared to diabetes drugs, based on Orexigen Therapeutics Inc.’s announcement of an agreement with the agency on a cardiovascular outcomes trial for its obesity agent Contrave (naltrexone/bupropion).

Vivus Will Cut Population In Qnexa Resubmission

The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel